Words, words, and overheated words fly as U.K. officials keep grilling Pfizer

The war of words over the proposed Pfizer-AstraZeneca merger was already hot. Now, it's almost boiling. And as usual when the heat is on, some people can't handle it. They boil over. Here's what people are hearing:

  • One Labour party member of Parliament called Pfizer ($PFE) folks "rapists" in a tweet. A flurry of "we're offended" tweets followed. The MP, Austin Mitchell, has a foot-in-mouth history; now, some members of his own party are calling for his suspension. Report

  • Tuesday, AstraZeneca ($AZN) CEO Pascal Soriot said a Pfizer buyout would distract his troops from doing their jobs--and could disrupt development so much that people would die for lack of an AZ cancer-drug breakthrough. Wednesday, Pfizer chief Ian Read scoffed back: If anything, Pfizer would bring those drugs to market sooner. Deaths averted. Report

  • With accusations of broken Pfizer promises made in Sweden, the U.K. and the U.S., the wildlife metaphors are flying: Pfizer is a blood-sucking praying mantis; Pfizer is a shark that needs feeding. "[I]s this a leopard that has changed its spots?" a Parliamentary committee chair asked Read during a Tuesday hearing. The answer, per Read? No need, because Pfizer has kept its promises. Report

  • Labour Party leader Ed Miliband, who's been an outspoken critic of the merger from the get-go, called Pfizer's promises on jobs and R&D "worthless." Some British officials are demanding guarantees lasting 10 years--or more. "A commitment of at least 10 years is required," a top British scientist, Paul Nurse, wrote in a letter to Parliament's science committee, which held its own hearings today. Report

  • One of the few still speaking in business jargon is Read, who used words like "opportunity" and "complementary" and "outcomes." The clause "I suspect" popped up repeatedly: "I suspect there will less scientists" after the merger; "I suspect the combined research budget will go down." But Pfizer won't "under-invest" in the post-merger business, he said. Pfizer would "ringfence any important products" of AstraZeneca's to keep them moving forward. And then there's the all-purpose "no way of knowing" what he might find when and if he gets to AstraZeneca's books. As for job numbers? "I can't tell today," he said. Report | Report (sub. req.)

  • Another sober analysis? The Wall Street Journal's look at AstraZeneca's future prospects versus the up-front, in-hand return Pfizer is offering. If AZ rebuffs Pfizer, then shareholders should demand accountability for current management, the WSJ says. Tie exec pay to the company's latest long-term estimates, for instance. Report (sub. req.)

Special Reports: Top 10 pharma companies by 2013 revenue - Pfizer - AstraZeneca

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.